p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos.

Epidemiological studies have shown that asbestos fibers constitute the major occupational risk factor and that asbestos acts synergistically with tobacco smoking to induce lung cancer. Although some somatic gene alterations in lung cancer have been linked to tobacco smoke, few data are available on the role of asbestos fibers. P16/CDKN2A is an important tumor suppressor gene that is frequently altered in lung cancer via promoter 5'-CpG island hypermethylation and homozygous deletion, and rarely via point mutation. Many studies suggest that tobacco smoking produces P16/CDKN2A promoter hypermethylation in lung cancer, but the status of this gene in relation to asbestos exposure has yet to be determined. The purpose of this study was to investigate the mechanism of P16/CDKN2A alterations in lung cancer in asbestos-exposed patients. P16/CDKN2A gene status was studied in 75 human non-small-cell lung cancer (NSCLC) cases with well-defined smoking habits, and detailed assessment of asbestos exposure, based on occupational questionnaire and determination of asbestos bodies in lung tissue. The results of this study confirm published data on the effect of tobacco smoke on P16/CDKN2A gene alterations, characterized by significantly higher P16/CDKN2A promoter hypermethylation in heavy smokers (more than 40 pack-years (P-Y)) than in smokers of less than 40 P-Y. These results also demonstrate a higher incidence of loss of heterozygosity and homozygous deletion in asbestos-exposed cases, after adjustment for age and cumulative tobacco consumption, than in unexposed cases (P=0.0062). This study suggests that P16/CDKN2A gene inactivation in asbestos-exposed NSCLC cases mainly occurs via deletion, a feature also found in malignant mesothelioma, a tumor independent of tobacco smoking but associated with asbestos exposure, suggesting a possible relationship with an effect of asbestos fibers.

[1]  F. Gilliland,et al.  Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. , 2002, Cancer research.

[2]  K. Kelsey,et al.  Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer , 2006, International journal of cancer.

[3]  L. Thiberville,et al.  Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: A prospective study in high‐risk patients without invasive cancer. , 2002, International journal of cancer.

[4]  P. Hainaut,et al.  Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. , 2007, Cancer research.

[5]  Chris Jones,et al.  CpG island methylation , 2000, Breast Cancer Research.

[6]  M. Jaurand,et al.  Role of fibre characteristics on cytotoxicity and induction of anaphase/telophase aberrations in rat pleural mesothelial cells in vitro: correlations with in vivo animal findings. , 1995, Carcinogenesis.

[7]  P. Laurent-Puig,et al.  Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma , 2008, BMC Medical Genomics.

[8]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[9]  A. Tossavainen,et al.  Guidelines for mineral fibre analyses in biological samples: report of the ERS Working Group. European Respiratory Society. , 1998, The European respiratory journal.

[10]  P. Boffetta.  Human cancer from environmental pollutants: the epidemiological evidence. , 2006, Mutation research.

[11]  S. Burdach,et al.  CpG island methylation and expression of tumour-associated genes in lung carcinoma. , 2005, European journal of cancer.

[12]  E. Mark,et al.  p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. , 2001, Cancer research.

[13]  D. Stoppa-Lyonnet,et al.  Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. , 1998, Human molecular genetics.

[14]  E. C. Hammond,et al.  Asbestos and smoking. , 1979, JAMA.

[15]  S. Hecht,et al.  Tobacco smoke carcinogens and lung cancer. , 1999, Journal of the National Cancer Institute.

[16]  J. Testa,et al.  Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma , 1999, Journal of cellular physiology.

[17]  M. Morita,et al.  The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. , 2006, Cancer.

[18]  C. Carpenter,et al.  DNA methylation analysis: a powerful new tool for lung cancer diagnosis , 2002, Oncogene.

[19]  G. Serio,et al.  Cytogenetic and molecular genetic changes in malignant mesothelioma. , 2006, Cancer genetics and cytogenetics.

[20]  J. Herman,et al.  Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. , 2001, Cancer research.

[21]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[22]  G. Peters,et al.  The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.

[23]  M. Morita,et al.  The methylation status and protein expression of CDH1, p16INK4A, and fragile histidine triad in nonsmall cell lung carcinoma , 2006 .

[24]  J. Subramanian,et al.  Molecular genetics of lung cancer in people who have never smoked. , 2008, The Lancet. Oncology.

[25]  J. Testa,et al.  Somatic genetic alterations in human malignant mesothelioma (review). , 1999, International journal of oncology.

[26]  Diane D. Liu,et al.  Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. , 2002, Cancer research.

[27]  M. Ladanyi,et al.  Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[29]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. Motoyama,et al.  Frequent Epigenetic Silencing of the p16 Gene in Non‐small Cell Lung Cancers of Tobacco Smokers , 2002, Japanese journal of cancer research : Gann.

[31]  J. Minna,et al.  Dose effect of smoking on aberrant methylation in non‐small cell lung cancers , 2004, International journal of cancer.

[32]  John K. Wiencke,et al.  p16INK4a and Histology-specific Methylation of CpG Islands by Exposure to Tobacco Smoke in Non-Small Cell Lung Cancer , 2001 .

[33]  H. Dosaka-akita,et al.  Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers , 1999, British Journal of Cancer.

[34]  Ling Li,et al.  Hypermethylation of p 16 INK 4 a in Chinese lung cancer patients : biological and clinical implications , 2003 .

[35]  J. Pairon,et al.  Pleural mesothelioma and exposure to asbestos: evaluation from work histories and analysis of asbestos bodies in bronchoalveolar lavage fluid or lung tissue in 131 patients. , 1994, Occupational and environmental medicine.

[36]  Shujun Cheng,et al.  Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. , 2003, Carcinogenesis.

[37]  H. Cavé,et al.  Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma , 2004, British Journal of Cancer.

[38]  M. Spitz,et al.  Aberrant Promoter Methylation Profile and Association with Survival in Patients with Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[39]  Kenji Suzuki,et al.  Association of p16 Homozygous Deletions with Clinicopathologic Characteristics and EGFR/KRAS/p53 Mutations in Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[40]  J. Minna,et al.  Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  Marco Di Giovanni,et al.  Similar Tumor Suppressor Gene Alteration Profiles in Asbestos-Induced Murine and Human Mesothelioma , 2005, Cell cycle.

[42]  A. Collins,et al.  Genotoxic effects of asbestos in humans. , 2004, Mutation research.

[43]  G. Gordon,et al.  Alterations of the p16(INK4) locus in human malignant mesothelial tumors. , 2002, Carcinogenesis.

[44]  Markku Mikael Nurminen,et al.  Epidemiologic estimate of the proportion of fatalities related to occupational factors in Finland. , 2001, Scandinavian journal of work, environment & health.

[45]  Mary Ellen Kitler,et al.  European Respiratory Society , 2005, International Journal of Pharmaceutical Medicine.

[46]  Olav Axelson,et al.  Alternative for estimating the burden of lung cancer from occupational exposures--some calculations based on data from Swedish men. , 2002, Scandinavian journal of work, environment & health.

[47]  M. Ladanyi.  Implications of P16/CDKN2A deletion in pleural mesotheliomas. , 2005, Lung cancer.

[48]  V. Gouyer,et al.  Mechanisms of p16INK4A inactivation in non small-cell lung cancers , 1998, Oncogene.

[49]  S. Anttila,et al.  Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer , 2003, International journal of cancer.

[50]  S. Jhanwar,et al.  A mouse model recapitulating molecular features of human mesothelioma. , 2005, Cancer research.

[51]  T. Nakajima,et al.  Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non‐small cell lung cancers , 1998, International journal of cancer.

[52]  J. Yokota,et al.  How many tumor suppressor genes are involved in human lung carcinogenesis? , 1999, Carcinogenesis.

[53]  P. Hainaut,et al.  TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. , 2005, Cancer research.